10-09-2020

Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100

---

09-17-2020

BOLD-100 Shows Inhibition of DNA Repair Pathways in Breast Cancer

---

08-17-2020

BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model

---

07-15-2020

BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro

---

06-11-2020

 Bold Therapeutics Expands COVID-19 Consortium 

---

05-28-2020

Bold Therapeutics and Hana Pharm Execute Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea

---

04-15-2020

Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19

---

03-27-2020

Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate Has Potential Utility in the Treatment of COVID-19

---

03-27-2020

Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in GI Cancers

---

02-10-2020

Bold Therapeutics Visiting Collaborators in Europe

---